Copenhagen, Denmark, March 27, 2025-Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based ...
Copenhagen, Denmark, March 27, 2025-Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based ...
Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...
MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726 ...
Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with ...
Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease congenital hyperinsulinism (CHI) to the US market. For the second time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback